---
title: "PuraPharm Revenue Drops but Annual Loss Holds Steady in 2025"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/280552673.md"
description: "PuraPharm Corp. Ltd. reported a 12% decline in 2025 revenue to HK$336.1 million, primarily due to falling sales in its core Chinese medicine granules and clinics. Despite this, the company's net loss remained stable at HK$35.2 million, indicating some cost control measures. Growth in Chinese healthcare products by nearly 10% suggests a shift in revenue sources. The latest analyst rating for PuraPharm's stock (HK:1498) is a Sell, with a price target of HK$0.33, reflecting ongoing challenges in the competitive healthcare market."
datetime: "2026-03-25T22:39:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280552673.md)
  - [en](https://longbridge.com/en/news/280552673.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280552673.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280552673.md) | [English](https://longbridge.com/en/news/280552673.md)


# PuraPharm Revenue Drops but Annual Loss Holds Steady in 2025

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

An announcement from PuraPharm Corp. Ltd. ( (HK:1498) ) is now available.

PuraPharm Corporation Limited reported a 12% year-on-year decline in 2025 revenue to HK$336.1 million, as sales of Hong Kong concentrated Chinese medicine granules and Nong’s-branded clinics fell and China concentrated granule and plantation revenue almost disappeared. Chinese healthcare products were a bright spot with nearly 10% growth, and despite lower gross profit and reduced other income, the group’s net loss was broadly unchanged at HK$35.2 million, highlighting continued earnings pressure but some cost control and credit loss reversals.

The company’s performance underscores a challenging operating environment for its core traditional Chinese medicine granule and clinic businesses, while growth in healthcare products suggests a shifting revenue mix. Stable losses, reduced selling and administrative expenses and a reversal of impairment on financial assets point to ongoing restructuring and efficiency efforts, with implications for how PuraPharm balances legacy segments against faster-growing product lines in a competitive healthcare landscape.

The most recent analyst rating on (HK:1498) stock is a Sell with a HK$0.33 price target. To see the full list of analyst forecasts on PuraPharm Corp. Ltd. stock, see the HK:1498 Stock Forecast page.

**More about PuraPharm Corp. Ltd.**

PuraPharm Corporation Limited is a Hong Kong-based provider of concentrated Chinese medicine granules, Chinese healthcare products and Nong’s-branded Chinese medicine clinics. The group also has exposure to plantation and related activities in China, positioning it within the traditional Chinese medicine and broader healthcare market in the region.

**Average Trading Volume:** 213,928

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$168.5M

### 相關股票

- [PURAPHARM (01498.HK)](https://longbridge.com/zh-HK/quote/01498.HK.md)

## 相關資訊與研究

- [Rosslyn Chair Increases Stake Following Fundraising](https://longbridge.com/zh-HK/news/281366701.md)
- [China Cultural Tourism and Agriculture Group Tightens Remuneration Committee Mandate](https://longbridge.com/zh-HK/news/281495680.md)
- [ADVISORY-Alert incorrectly tagged to Apex Capital and Finance withdrawn](https://longbridge.com/zh-HK/news/281358690.md)
- [BSF Enterprise Raises £385,000 in Share Placing and Appoints New Financial Adviser](https://longbridge.com/zh-HK/news/281541909.md)
- [11:01 ETPureHealth Research Liver Health Supplements Target Fatty Liver for Improved Daily Energy](https://longbridge.com/zh-HK/news/281689012.md)